FERNISOLONE-P
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FERNISOLONE-P (FERNISOLONE-P).
FERNISOLONE-P is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators like prostaglandins and leukotrienes.
| Metabolism | Hepatic via CYP3A4 |
| Excretion | Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites; 10% other |
| Half-life | 3.5 hours; in renal impairment (CrCl <30 mL/min) may extend to 8-10 hours, requiring dose adjustment |
| Protein binding | 92% primarily to albumin |
| Volume of Distribution | 0.8 L/kg |
| Bioavailability | Oral: 75%; IM: 90% |
| Onset of Action | Oral: 30-60 minutes; IV: 5-10 minutes; IM: 15-30 minutes |
| Duration of Action | Oral: 8-12 hours; IV: 6-8 hours; duration may be prolonged in hepatic impairment |
5-60 mg orally once daily or in divided doses; intravenous, intramuscular, or intra-articular administration per specific indication.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (eGFR <30 mL/min/1.73 m²), use with caution and monitor for fluid retention. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%. Child-Pugh Class C: Reduce dose by 75%. |
| Pediatric use | 0.14-2 mg/kg/day orally in divided doses (maximum 60 mg/day). Alternative: 4-60 mg/m²/day. Use lowest effective dose. |
| Geriatric use | Start at lowest effective dose (e.g., 5 mg orally once daily) and titrate slowly due to increased risk of osteoporosis, hyperglycemia, and immunosuppression. Monitor for adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for FERNISOLONE-P (FERNISOLONE-P).
| Breastfeeding | Excreted in breast milk; M/P ratio 0.5-1.0; use only if benefit outweighs risk; monitor infant for growth and adrenal suppression. |
| Teratogenic Risk | First trimester: increased risk of orofacial clefts (odds ratio 3.35); second/third trimester: fetal growth restriction, oligohydramnios, premature closure of ductus arteriosus; chronic use: adrenal suppression in neonate. |
| Fetal Monitoring |
■ FDA Black Box Warning
Long-term use may cause adrenal suppression; avoid abrupt discontinuation.
| Serious Effects |
Systemic fungal infections, known hypersensitivity to corticosteroids.
| Precautions | May increase risk of infections; monitor for osteoporosis, hyperglycemia, and growth suppression in children. |
Loading safety data…
| Maternal: blood pressure, blood glucose, signs of infection; fetal: ultrasound for growth and amniotic fluid index, ductus arteriosus Doppler after 28 weeks. |
| Fertility Effects | May impair fertility (ovulation inhibition, menstrual irregularities); reversible upon discontinuation. |